Plosaracetam

Last updated

Plosaracetam
Plosaracetam.svg
Clinical data
Other namesABBV-552; ABBV552; SDI-118; SDI118
Routes of
administration
Oral [1]
Drug class Synaptic vesicle glycoprotein 2A (SV2A) ligand [2]
Identifiers
  • (4R)-1-[(5-chloro-1,2,4-triazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C13H10ClF3N4O
Molar mass 330.70 g·mol−1
3D model (JSmol)
  • C1[C@@H](CN(C1=O)CN2C(=NC=N2)Cl)C3=CC(=C(C(=C3)F)F)F
  • InChI=1S/C13H10ClF3N4O/c14-13-18-5-19-21(13)6-20-4-8(3-11(20)22)7-1-9(15)12(17)10(16)2-7/h1-2,5,8H,3-4,6H2/t8-/m0/s1
  • Key:GPGBFZCJDZALPN-QMMMGPOBSA-N

Plosaracetam (INN Tooltip International Nonproprietary Name; developmental code names ABBV-552, SDI-118) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of Alzheimer's disease and other cognition disorders. [1] [3] [4] [2] In contrast to earlier SV2A ligands like levetiracetam and brivaracetam, polsaracetam does not have anticonvulsant activity and instead shows pro-cognitive effects. [2] The drug is being developed by UCB Biopharma and AbbVie. [1] [3] As of October 2024, it is in phase 2 clinical trials for Alzheimer's disease and phase 1 trials for cognition disorders. [1] [3]

References

  1. 1 2 3 4 "ABBV 552". AdisInsight. 28 October 2024. Retrieved 26 February 2025.
  2. 1 2 3 Botermans W, Koole M, Van Laere K, Savidge JR, Kemp JA, Sunaert S, et al. (2022). "SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement". Frontiers in Pharmacology. 13: 1066447. doi: 10.3389/fphar.2022.1066447 . PMC   9887116 . PMID   36733374.
  3. 1 2 3 "Delving into the Latest Updates on Plosaracetam with Synapse". Synapse. 22 February 2025. Retrieved 26 February 2025.
  4. "ABBV-552". ALZFORUM. 28 February 2023. Retrieved 26 February 2025.